Investigating the impact of coincident modulation of adenosine and glutamate receptors on neuronal activity – implications for CNS drug discovery

研究同时调节腺苷和谷氨酸受体对神经元活动的影响 — 对中枢神经系统药物发现的影响

• 批准号: nhmrc : GNT1123722
• 负责人: Dr Andrea Vernall
• 金额: $ 64.84万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/investigating-impact-coincident-drug-discovery/1347362
• 关键词: Investigating; impact; coincident; modulation; adenosine

Dementia in particular Alzheimer's disease, is one of the leading causes of death. There remains a need for new drugs to treat both symptoms and disease progression. Two receptors in the brain, the adenosine A1 (A1AR) and metabotropic glutamate 5 (mGlu5) are suggested to be promising new drug targets for dementia. In order to better develop drugs that target these receptors, we will develop a better understanding of activity of these receptors under conditions of health and disease.

痴呆症，特别是阿尔茨海默病，是导致死亡的主要原因之一。仍然需要新药来治疗症状和疾病进展。大脑中的两种受体，腺苷 A1 (A1AR) 和代谢型谷氨酸 5 (mGlu5) 被认为是治疗痴呆症的有希望的新药物靶点。为了更好地开发针对这些受体的药物，我们将更好地了解这些受体在健康和疾病条件下的活性。